Streetbeat News

GNLX

Genelux Corporation

https://www.genelux.com

Industry

Biotechnology

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Open

2.53

Mkt cap

88M

Volume

194K

High

2.57

P/E Ratio

-2.71

52-wk high

16.60

Low

2.40

Div yield

N/A

52-wk low

1.60

Benchmark analyst Bruce Jackson maintains a Speculative Buy rating on Genelux (NASDAQ:GNLX) but lowers the price target from $30 to $25.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 3:12 pm

The article highlights significant intraday movements in health care stocks on Monday. Notable gainers include Innovative Eyewear (LUCY), OneMedNet (ONMD), Qilian Intl Hldg Gr (QLI), Onconetix (ONCO), TransCode Therapeutics (RNAZ), and MultiPlan (MPLN). Major losers include Verastem (VSTM), Sensei Biotherapeutics (SNSE), Genelux (GNLX), Candel Therapeutics (CADL), Exicure (XCUR), and HOOKIPA Pharma (HOOK).

Portfolio Pulse from Benzinga Insights

May 27, 2024 | 4:31 pm

The article highlights the pre-market movements of various health care stocks on Monday. Notable gainers include Cue Health (HLTH), SCWorx (WORX), Innovative Eyewear (LUCY), Vaccinex (VCNX), Guardant Health (GH), and Scinai Immunotherapeutics (SCNI). Significant losers include Verastem (VSTM), Sensei Biotherapeutics (SNSE), Genelux (GNLX), Summit Therapeutics (SMMT), Akari Therapeutics (AKTX), and Candel Therapeutics (CADL).

Portfolio Pulse from Benzinga Insights

May 27, 2024 | 12:05 pm

U.S. stocks traded higher with the Nasdaq Composite gaining over 1%. Notable stock movements included Akanda Corp. (AKAN) rising 34% after a reverse stock split, Merus N.V. (MRUS) surging 34% following an abstract publication, and Deckers Outdoor Corporation (DECK) increasing 13% due to strong quarterly results. Conversely, Verastem, Inc. (VSTM) shares plummeted 65% after initiating a rolling NDA submission, TriSalus Life Sciences, Inc. (TLSI) fell 21% amid an exchange offer, and Genelux Corporation (GNLX) dropped 41% following a stock offering announcement.

Portfolio Pulse from Avi Kapoor

May 24, 2024 | 6:47 pm

NetEase, Inc. (NASDAQ:NTES) shares fell 4% after reporting worse-than-expected first-quarter revenue. Despite a 7.2% year-on-year revenue growth to $3.72 billion, it missed the analyst consensus estimate of $3.79 billion. However, the company's adjusted EPADS of $1.81 beat the consensus estimate of $1.79. Other stocks moving significantly include Akanda Corp. (NASDAQ:AKAN), OneMedNet Corporation (NASDAQ:ONMD), and Verastem, Inc. (NASDAQ:VSTM).

Portfolio Pulse from Avi Kapoor

May 24, 2024 | 5:57 pm

The article highlights significant intraday movements in health care stocks on Friday. Notable gainers include Innovative Eyewear (LUCY), OneMedNet (ONMD), TransCode Therapeutics (RNAZ), Onconetix (ONCO), Aptorum Group (APM), and Immatics (IMTX). Major losers include Verastem (VSTM), Sensei Biotherapeutics (SNSE), Genelux (GNLX), Exicure (XCUR), TriSalus Life Sciences (TLSI), and HOOKIPA Pharma (HOOK).

Portfolio Pulse from Benzinga Insights

May 24, 2024 | 4:31 pm

Genelux shares are trading lower following the announcement of a $27.5 million underwritten offering of common stock and accompanying warrants.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 4:22 pm

U.S. stocks traded higher with the Nasdaq Composite gaining around 1%. Intuit shares fell 8% despite better-than-expected earnings due to weak guidance. Akanda Corp. shares surged 70% after a reverse stock split. Merus N.V. shares rose 37% following a positive abstract publication. Deckers Outdoor Corporation shares increased 13% on strong quarterly results. Verastem, Inc. shares dropped 61% after initiating a rolling NDA submission. TriSalus Life Sciences shares fell 26% following an exchange offer announcement. Genelux Corporation shares declined 45% after pricing a $27.5 million stock offering.

Portfolio Pulse from Avi Kapoor

May 24, 2024 | 4:07 pm

Genelux Corporation (NASDAQ:GNLX) shares dropped by 40.7% to $2.73 after announcing an underwritten offering of 6.875 million shares and accompanying warrants at $4.00 each. The offering aims to raise approximately $27.5 million before expenses to support corporate activities and the clinical development of Olvi-Vec. The offering is expected to close around May 29, 2024.

Portfolio Pulse from Henry Khederian

May 24, 2024 | 3:19 pm

U.S. stocks traded higher with the Dow Jones gaining 50 points. Durable goods orders increased by 0.7% in April, surpassing expectations. Akanda Corp., Netcapital Inc., and Better Choice Company Inc. saw significant stock price increases, while Verastem, Inc., Sensei Biotherapeutics, Inc., and Genelux Corporation experienced notable declines.

Portfolio Pulse from Avi Kapoor

May 24, 2024 | 1:43 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.